Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
eyelid breakouts (such as chalaizons and styes), or other types of infections. Therefore, if your puffy eyes are accompanied by persisting pain, discomfort, or changes in vision, reach out to your eye ...